TRCT
BRNS

Tower Research Capital (TRC)’s Barinthus Biotherapeutics BRNS Stock Holding History

Tower Research Capital (TRC)’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$309 – 5931
2023
Q3 		$309 Sell
100
-22
-18% -$47 ﹤0.01% 5615
2023
Q2 		$251 Buy
+122
New +$289 ﹤0.01% 5719

Other funds holding BRNS

MGIM
M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

Tower Research Capital (TRC)'s BRNS Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of Barinthus Biotherapeutics (BRNS) in Q4 2023, closing a stake of 100 shares — an estimated $309 sold.

Tower Research Capital (TRC) first reported a position in BRNS in Q2 2023 and held it in 2 quarters. The position peaked at $309 in Q3 2023. 15 funds tracked by Wall St. Rank hold BRNS as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining Barinthus Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 100 Barinthus Biotherapeutics shares in Q4 2023, an estimated $309.
  • Tower Research Capital (TRC) first reported a position in Barinthus Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Tower Research Capital (TRC)'s Barinthus Biotherapeutics position peaked at $309 in Q3 2023.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.